The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding ...

We recently published a list of 10 AI Stocks on Analysts’ Radar As AI Spending Grows. In this article, we are going to take a ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on ...

Tempus AI (TEM) reports Q4 earnings Monday, expected loss of 20 cents/share, $203.12M in revenues. Stock up 98.80% YTD.

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...

Reports Q4 revenue $200.7M, consensus $202.8M. “Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to ...

EST Tempus AI (TEM) down 7% at $64.83 after Q4 earnings miss and guidanceDiscover the Best Stocks and Maximize Your Portfolio: See what ...

Q4 2024 Earnings Call Transcript February 24, 2025 Tempus AI, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.15. Operator: Thank you for standing by. My name ...

Would you like to be notified of the latest news and updates on the stock market?

Tempus posted a fourth-quarter adjusted net loss of $0.18 per share, $0.02 more per share than estimates by analysts surveyed by Visible Alpha. Revenue jumped 36% year-over-year to $200.7 million, but ...

The health care technology company posted revenue of $200.7 million in the period. For the year, the company reported a loss of $705.8 million, or $6.23 per share. Revenue was reported as $693.4 ...

CHICAGO - Tempus AI , Inc. (NASDAQ:TEM ... Tempus said its genomics business generated $120.4 million in Q4 revenue, up 30.6% YoY, while data and services revenue grew 44.6% to $80.2 million.